Different microtubule-targeting agents (MTAs) possess distinct modes of action and their clinical use in cancer treatment is often limited by chemotherapy-induced peripheral neurotoxicity (CIPN). Eribulin is a member of the halichondrin class of antineoplastic drugs, which is correlated with a high antimitotic activity against metastatic breast cancer and liposarcoma. Current clinical evidence suggests that eribulin treatment, unlike some of the other MTAs, is associated with a relatively low incidence of severe peripheral neuropathy. This suggests that different MTAs possess unique mechanisms of neuropathologic induction. Animal models reliably reproduced eribulin-related neuropathy providing newer insights in CIPN pathogenesis, and they are highly suitable for in vivo functional, symptomatic and morphological characterizations of eribulin-related CIPN. The purpose of this review is to discuss the most recent literature on eribulin with a focus on both clinical and preclinical data, to explain the molecular events responsible for its favorable neurotoxic profile.

Tarasiuk, O., Cavaletti, G., Meregalli, C. (2022). Clinical and preclinical features of eribulin-related peripheral neuropathy. EXPERIMENTAL NEUROLOGY, 348(February 2022) [10.1016/j.expneurol.2021.113925].

Clinical and preclinical features of eribulin-related peripheral neuropathy

Tarasiuk O.
Primo
;
Cavaletti G.
Secondo
;
Meregalli C.
Ultimo
2022

Abstract

Different microtubule-targeting agents (MTAs) possess distinct modes of action and their clinical use in cancer treatment is often limited by chemotherapy-induced peripheral neurotoxicity (CIPN). Eribulin is a member of the halichondrin class of antineoplastic drugs, which is correlated with a high antimitotic activity against metastatic breast cancer and liposarcoma. Current clinical evidence suggests that eribulin treatment, unlike some of the other MTAs, is associated with a relatively low incidence of severe peripheral neuropathy. This suggests that different MTAs possess unique mechanisms of neuropathologic induction. Animal models reliably reproduced eribulin-related neuropathy providing newer insights in CIPN pathogenesis, and they are highly suitable for in vivo functional, symptomatic and morphological characterizations of eribulin-related CIPN. The purpose of this review is to discuss the most recent literature on eribulin with a focus on both clinical and preclinical data, to explain the molecular events responsible for its favorable neurotoxic profile.
Articolo in rivista - Articolo scientifico
Chemotherapy-induced peripheral neuropathy; Clinical; Eribulin mesylate; Microtubule-targeting agents; Molecular mechanisms; Preclinical; Review;
English
18-set-2021
2022
348
February 2022
113925
none
Tarasiuk, O., Cavaletti, G., Meregalli, C. (2022). Clinical and preclinical features of eribulin-related peripheral neuropathy. EXPERIMENTAL NEUROLOGY, 348(February 2022) [10.1016/j.expneurol.2021.113925].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/345859
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
Social impact